Skip to main content
. 2020 May 19;12(5):1283. doi: 10.3390/cancers12051283

Figure 3.

Figure 3

Cell proliferation inhibition of FASN inhibitors in parental and Gefitinib Resistant (GR) models. Sensitive (PC9) and GR models (PC9-GR1, PC9-GR3, and PC9-GR4) were treated with increasing concentrations of (a) EGCG (5–150 µM) and (b) G28 (2–40 µM) for 72 h. Results shown are expressed as the percentage of surviving cells after drug treatment (mean ± SE) and are representative from at least three independent experiments.